CACA guidelines for holistic integrative management of glioma
-
Published:2022-12-22
Issue:1
Volume:1
Page:
-
ISSN:2731-4529
-
Container-title:Holistic Integrative Oncology
-
language:en
-
Short-container-title:Holist Integ Oncol
Author:
Fan Daiming, Jiang TaoORCID, Ma Wenbin, Jiang Chuanlu, You Yongping, Mao Ying, Qiu Xiaoguang, Kang Chunsheng, Li Gang, Mao Qing, Yang Xuejun, Qin Zhiyong, Liu Zhixiong, Wang Weimin, Wei Xinting, Li Wenbin, Liu Yunhui, Yu Rutong, Yu Xinguang, Kang Dezhi, Mou Yonggao, Wang Lei, Zhang Wei, Bao Zhaoshi, Chai Ruichao, Chen Baoshi, Fan Xing, Fang Shengyu, Li Guanzhang, Li Lianwang, Li Shouwei, Liu Xing, Liu Yanwei, Shan Xia, Wang Liang, Wang Yinyan, Wang Yu, Wang Zheng, Wang Zhiliang, Wu Chenxing, Yan Wei, Yang Pei, You Gan, Zhang Chuanbao, Zhang Zhong, Zhao Zheng
Abstract
AbstractGlioma of the brain is a kind of tumor originating from neuroglial cells. It is the most common primary intracranial tumor, accounting for ~ 30% of all central nervous system tumors and 80% of malignant brain tumors. Glioma is characterized by high disability and recurrence rates. The disease seriously threatens the life of patients, affects their quality of life, and brings a heavy economic and psychological burden to patients, families, and society.With the progression of molecular genetic testing technology and the completion of various clinical trials, the classification scheme for glioma is increasingly well established. Diagnosis and treatment regimens, including traditional and new regimens, are becoming increasingly specialized and standardized. The purpose is to develop a clinical diagnosis and treatment guideline for glioma in the Chinese population suitable for Chinese doctors and the general population based on domestic and international glioma research progress. Thus, domestic practitioners in the field can obtain current information and provide better service to patients with glioma, promoting the development of domestic clinical medicine and basic research on glioma.
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Commission MAaHAotNH. Guidelines for the diagnosis and treatment of gliomas (2018 edition). Chin J Neurosurg. 2019;35(3):217–39. https://doi.org/10.3760/cma.j.issn.1001-2346.2019.03.001. 2. Patel AP, Fisher JL, Nichols E, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376–93. https://doi.org/10.1016/s1474-4422(18)30468-x. 3. Jiang T, Tang GF, Lin Y, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J (Engl). 2011;124(17):2578–83. 4. Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–105. https://doi.org/10.1093/neuonc/noab200. 5. Suchorska B, Giese A, Biczok A, et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol. 2018;20(2):279–88. https://doi.org/10.1093/neuonc/nox153.
|
|